Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Medecine Sciences : M/S
|
September 2, 2011
[Histone methyltransferases: a new class of therapeutic targets in cancer treatment?]
Hassiba Chaib, Thomas Prébet, Norbert Vey, et al.
Cell Cycle (Georgetown, Tex.)
|
March 19, 2011
PTK7: a cell polarity receptor with multiple facets
Anne-Catherine Lhoumeau, Francesca Puppo, Thomas Prébet, et al.
Biotechniques
|
October 27, 2009
A simplified, 96-well-adapted, ATP luminescence-based motility assay
Audrey Restouin, Sandra Aresta, Thomas Prébet, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
May 29, 2004
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes
Thomas Prébet, Sophie Ducastelle, Stephan Debotton, et al.
Leukemia & Lymphoma
|
May 16, 2012
Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction
Thomas Prébet, Estelle Jean, Aurélie Autret, et al.
Oncotarget
|
November 17, 2016
Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
Sarah Bertoli, Arthur Sterin, Suzanne Tavitian, et al.
Experimental Hematology
|
October 20, 2009
Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation
Thomas Prébet, Patrick Ladaique, Martin Ferrando, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
Thomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Haematologica
|
March 15, 2006
Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia
Sophie Ducastelle, Lionel Adès, Claude Gardin, et al.
Leukemia Research
|
July 8, 2010
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone
Franck E Nicolini, Sandrine Hayette, Laurence Legros, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Medecine Sciences : M/S
|
September 2, 2011
[Histone methyltransferases: a new class of therapeutic targets in cancer treatment?]
Hassiba Chaib, Thomas Prébet, Norbert Vey, et al.
Cell Cycle (Georgetown, Tex.)
|
March 19, 2011
PTK7: a cell polarity receptor with multiple facets
Anne-Catherine Lhoumeau, Francesca Puppo, Thomas Prébet, et al.
Biotechniques
|
October 27, 2009
A simplified, 96-well-adapted, ATP luminescence-based motility assay
Audrey Restouin, Sandra Aresta, Thomas Prébet, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
May 29, 2004
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes
Thomas Prébet, Sophie Ducastelle, Stephan Debotton, et al.
Leukemia & Lymphoma
|
May 16, 2012
Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction
Thomas Prébet, Estelle Jean, Aurélie Autret, et al.
Oncotarget
|
November 17, 2016
Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
Sarah Bertoli, Arthur Sterin, Suzanne Tavitian, et al.
Experimental Hematology
|
October 20, 2009
Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation
Thomas Prébet, Patrick Ladaique, Martin Ferrando, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
Thomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Haematologica
|
March 15, 2006
Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia
Sophie Ducastelle, Lionel Adès, Claude Gardin, et al.
Leukemia Research
|
July 8, 2010
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone
Franck E Nicolini, Sandrine Hayette, Laurence Legros, et al.
Page
of 2